Search results for "triazol"

Synthesis of alkyl-5,8-dimethyl-6-phenyl-5,6-dihydropyrazolo[3,4-f] [1,2,3,5]tetrazepin-4(3H)-ones of pharmaceutical interest

2006

The multistep synthesis of two pyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one derivatives, a new class of fused 1,2,3,5-tetrazepinones with potential antiproliferative activity, has been carried out. Owing to the instability of the above compounds, the last step of the synthesis was performed at -5/0 degrees C. The obtained tetrazepinones, when allowed to stand at r.t. for 24 h, afforded quantitatively 1-phenyl-3,6-dimethylpyrazolo [3,4-d][1,2,3] triazole.

Triazolopyridines 22.1 Description of new 7,9-di(2-pyridyl)[1,2,3]triazolo[5',1':6,1]pyrido[3,2-d]pyrimidines

2002

The new heteroaromatic compounds, 7,9-di(2-pyridyl)(1,2,3)triazolo(5',1':6,1)pyrido(3,2-d) pyrimidines 11a-c, were synthesized in two steps from readily available triazolopyridines 1a-c. Regioselective lithiation of 1a-c followed by treatment with 2-cyanopyridine gave a mixture of compounds 5a-c, and 11a-c in moderate to low yields, together with gums. Similar reactions with the triazolopyridine 1d gave as the only identified compound the triazolopyridine derivative 5d.

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program o…

2013

BACKGROUND Compliance and persistence are often overlooked in adjuvant breast cancer treatment. PATIENTS AND METHODS PACT was a prospective, multicenter, randomized, open, parallel-group study assessing whether educational materials (EMs) enhanced compliance with aromatase inhibitor (AI) therapy in postmenopausal women with early, hormone-receptor-positive (HR+) breast cancer. The primary end points were compliance (proportion taking ≥ 80% anastrozole) at 12 months and persistence (proportion reporting anastrozole intake during the study period). RESULTS Four thousand eight hundred and forty-four patients were randomly assigned 1:1 to receive standard therapy or standard therapy with EMs. T…

Iron Chelation Therapy in thalassaemia major: a sistematic review with meta-analyses of 1520 patients included on randomized clinical trials

2011

The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using χ2 (Q) and I2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p<0.0001), increases in serum ferritin levels during DFX 5, 1…

Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels.

2005

To evaluate the influence of dapiprazole versus brimonidine on pupil size at various illumination levels.Department of Ophthalmology, Johannes Gutenberg-University, Mainz, Germany.In randomized prospective study, 19 healthy volunteers received 2 ophthalmic solutions, dapiprazole and brimonidine, 1 in each eye, for intraindividual comparison. Before and after application, pupil diameter was measured using an infrared binocular pupillometer at 3 illumination levels (0.03, 0.82, and 6.4 lux).Only slight pupil dilation was observed under scotopic conditions after application of both agents. After 20 minutes, the median reduction in pupil width was 1.4 mm for brimonidine and 0.9 mm for dapiprazo…

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adju…

2014

5 Office-based Professional Association Gynecologic Oncologists e.V. in Germany (BNGO e.V.), Berlin; 6 Background: This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer. Patients and methods: COMPliance and Arthralgia in Clinical Therapy (COMPACT) was an open-label, multicenter, noninterventional study conducted in Germany. Patients had started adjuvant anastrozole 3-6 months before the study start. The primary end points were arthralgia, compliance, and the relationship between compliance and arthralgia, assessed at specific time poi…

Síntesis y caracterización de compuestos de Cu(II) con derivados triazólicos. Estudio de su actividad como potenciales nucleasas químicas

2014

The main goal of this PhD thesis concerns the development of artificial metallonucleases based on copper(II)-1,2,4-triazole compounds. In order to do so, we have obtained metal compounds of different nuclearities by reaction of a new family of 1,2,4-triazole ligands with copper(II) salts. The ligands own the characteristic triazole properties upon coordinating to metals and also integrate DNA binding units (aromatic moieties) with the aim of increasing the affinity of the corresponding metal complexes to double strand DNA. We have also chosen the copper(II) ion due to its intrinsic redox and coordination properties. Here we present our conclusions in relation with their structure/activity a…

Complessi di di- e triorganostagno(IV) con [1,2,4]triazolo-[1,5-a]pirimidina e suoi derivati 5- e 7-sostituiti

2004

Nuovi Riarrangiamenti Boulton-Katritzky di derivati 1,2,4-ossadiazolici contenenti un atomo di carbonio nucleofilo in catena laterale

2009

Synthesis of Amino-1,2,4-triazoles by Reductive ANRORC Rearrangements of 1,2,4-Oxadiazoles

2010

The reaction of various 1,2,4-oxadiazoles with an excess of hydrazine in DMF has been investigated. 3-Amino- 1,2,4-triazoles are produced through a reductive ANRORC pathway consisting of the addition of hydrazine to the 1,2,4-oxadiazole followed by ring-opening, ring-closure, and final reduction of the 3-hydroxylamino-1,2,4-triazole intermediate. The general applicability of 1,2,4-oxadiazoles ANRORC reactivity is demonstrated also in the absence of C(5)-linked electron-withdrawing groups.